Markets
markets
Luke Kawa

IBM “separating themselves from the pack,” added to Wedbush’s Best Ideas list

If you’ve read any of Dan Ives’ work, you’d know the Wedbush analyst is pretty bullish on the medium-term prospects for AI, deeming it a “once in a generation 4th Industrial Revolution.”

But like any good analyst, he’s got to make calls on which tech companies are going to be big beneficiaries of sea change and which will be taken out by the tide. To that end, he’s named IBM as the newest addition to Wedbush’s Best Ideas List. Shares are up about 1% in early trading.

“While there is a lot of noise in the software world around driving monetization of AI, a handful of software players have started to separate themselves from the pack,” he wrote. “The clear standout over the last month from checks has been the cloud penetration success at IBM which has a massive opportunity to monetize its installed base over the next 12 to 18 months.”

Big Blue is up 11% this year, far outstripping the 3.6% and 8% declines in the S&P 500 and US tech sector, respectively. Shares of the computing giant had their best day since 1999 after reporting surprisingly strong earnings in January, bolstered by big growth in its AI business.

“In a nutshell, investors remain nervous about the AI spending trajectory in this backdrop yet to the contrary we see many enterprises accelerating their strategic paths for 2025 which is bullish for the software ecosystem,” he added.

Earlier this month, Ives also added Tesla to his “Best Ideas” list.

More Markets

See all Markets
markets

Canopy rallies after CEO stock purchase

Canopy Growth rallied on Wednesday after its CEO, Luc Mongeau, disclosed an unplanned stock purchase on Tuesday.

Mongeau, who joined Canopy from Mars in January, bought 27,469 shares at CA$1.84. The buy is worth about US$36,259.

It has been a tumultuous time for cannabis stocks, as the market in Canada (where Canopy is located) stagnates and cannabis reform in the US has yet to move forward.

markets

Robinhood, new S&P 500 leader, the subject of favorable analyst chatter

Robinhood Markets briefly touched a new all-time intraday high in early trading after the newly minted — and now top-performing — member of the the S&P 500 received some favorable write-ups from Wall Street analysts.

(Robinhood Markets Inc. is the parent company of Sherwood Media, an independently operated media company subject to certain legal and regulatory restrictions. I own stock as part of my compensation.)

Piper Sandler analysts highlighted momentum in the company’s prediction markets business thanks to the rollout of contracts on college and profession football, noting that the event contracts business was running at a $200 million annualized rate so far in September. They raised their price target on the shares to $140 from $120.

“Prediction Markets (aka event contracts) present significant upside opportunity for Robinhood,” Piper Sandler’s Patrick Moley wrote.

Elsewhere, Citi analysts raised their Q3 and full-year 2025 estimates and upped their price target on the shares to $135, but kept a “neutral” rating on the stock.

“While HOOD continues to see solid momentum across the platform, we believe the stock is pricing in much of the growth potential in our view. Given current valuations and where we are in the retail cycle (closer to the highs than the lows from an activity perspective from our viewpoint), we prefer to wait for a more reasonable entry point at present.”

The stock has clearly had a heck of a run.

Through yesterday’s close, Robinhood was up nearly 240% in 2025. Since it was added to the S&P 500 on Monday, it’s now the top performer among the blue chips, trouncing previous leaders Seagate Technology Holdings and Palantir.

markets

UniQure surges after encouraging trial results for Huntington’s treatment

UniQure rose more than 150% in early trading Wednesday after it released trial results that showed its experimental gene therapy for Huntington’s disease slowed its progression by 75% after three years.

The treatment, AMT-130, is a one-time treatment for Huntington’s, a genetic brain disease that degrades cognitive function and muscle control. There is currently no cure for the disease.

UniQure said it plans to submit the treatment for approval to the Food and Drug Administration in the first quarter of 2026, meaning it could become available to patients later that year. The company currently makes nearly all of its revenue from gene therapies that treat hemophilia.

Halo of the sun

A tiny UK company is showing how easy it is to get an (undeserved?) Nvidia halo effect

Step 1: join a free Nvidia program. Step 2: watch stock go up. Step 3: watch stock go down.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.